Generic semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has recently become available in Canada after regulatory exclusivity for semaglutide expired in Canada in January 2026years earlier than expected in the US and countries in Europe
4 Moreover, Novo Nordisks recent SELECT trial demonstrated that Wegovy reduces the risk of cardiovascular events
Oral Electrolyte Solutions: If vomiting occurs, its vital to replenish lost fluids and electrolytes
Common overlapping side effects include gastrointestinal symptoms (nausea, vomiting, abdominal pain), increased heart rate and blood pressure, and excessive appetite suppression
Intravenous glutathione infusions bypass the digestive system but are unlicensed for NAFLD, not recommended by NICE, and carry risks including infection, contamination, and anaphylaxis when offered through private wellness clinics